Krystal Biotech, Inc. (KRYS) Profit Margins
Over the twelve months to 2026-06-30, Krystal Biotech, Inc. (KRYS) had gross margin 94.6%, operating margin 44.9%, net margin 54.8%, free cash flow margin 58.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KRYSKrystal Biotech, Inc.Follow KRYS — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- 39.0
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | 69.2% | 80.2% | 94.1% | 94.6% | |
| Operating margin | -216.2% | 22.6% | 41.5% | 44.9% | |
| Net margin | 21.6% | 30.7% | 52.6% | 54.8% | |
| FCF margin | -198.4% | 41.0% | 48.5% | 58.5% |
USD billions · SEC XBRL
Krystal Biotech, Inc. — questions
- What is Krystal Biotech, Inc.'s gross margin?
- 94.6% over the twelve months to 2026-06-30.
- What is Krystal Biotech, Inc.'s operating margin?
- 44.9% over the twelve months to 2026-06-30.
- What is Krystal Biotech, Inc.'s net profit margin?
- 54.8% over the twelve months to 2026-06-30.
Every figure on this page comes from Krystal Biotech, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.